Enlivex Reports Durable 12-Month Response With Allocetra In Knee Osteoarthritis Trial

Enlivex (ENLV) reported 12-month Phase I/IIa trial results for Allocetra, showing 79.2% of older patients with knee osteoarthritis experienced reduced pain and improved function vs. 47.6% with placebo. The therapy demonstrated a favorable safety profile. The company plans to present findings at ACR Convergence 2026 and expects Phase IIb trial data by Q2 2027. ENLV stock closed at $1.15, up 2.68%.

Original reporting
Published Nov 18, 2026, 2:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 2:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Enlivex Reports Durable 12-Month Response With Allocetra In Knee Osteoarthritis Trial — source image
Decision brief

The 30-second read

$ENLVBullishMed
01

Why it matters

The durable 12-month responder rates and favorable safety profile can strengthen the clinical narrative for Allocetra, but the stated absence of statistical significance for some individual measures at 12 months suggests investors may wait for Phase IIb topline to confirm efficacy.

02

Market read

Traders may adjust probabilities for Allocetra’s Phase IIb success based on durability and safety, while monitoring whether Phase IIb endpoints achieve statistical significance.

03

What to watch

Responder-rate comparisons are reported for older patients, but the article does not provide full statistical details, endpoint definitions, or effect sizes for the non-significant measures, which may matter for how investors underwrite Phase IIb odds.

Relevance 7/10Novelty 7/10Timing: today’s pre-market and near-term positioning ahead of ACR Convergence 2026 presentation and Phase IIb topline timing

Background

Allocetra is an investigational cell-based therapy targeting inflammation, dosed as a single cycle of three knee injections in a Phase I/IIa design with a safety stage and randomized, double-blind placebo-controlled Phase IIa stage.

Company-level read

Ticker impact

$ENLVBullishMedium confidence
Context

Enlivex reports positive 12-month Phase I/IIa Allocetra results in knee osteoarthritis, including 79.2% pain/function improvement vs 47.6% placebo in older patients.

Expected impact

Likely upward bias as traders price improved durability and safety, while noting that Phase IIa endpoint differences were not statistically significant at 12 months.

Evidence & confidence

The article provides specific 12-month responder rates and safety outcomes, but also flags that some individual measures were not statistically significant at that timepoint, limiting conviction until Phase IIb topline.

Market effects

Adds incremental evidence for cell-based/inflammation-targeting approaches in osteoarthritis, potentially improving sentiment toward similar biotech programs.

Limited, as the catalyst is company-specific clinical data for a foreign-listed issuer with a US-listed ticker.

Moderate for global biotech investors tracking durability and safety signals in musculoskeletal indications.

Counterpoint

The lack of statistical significance for individual pain and knee-function measures at 12 months could reduce enthusiasm, making the headline durability less decisive for valuation until Phase IIb confirms efficacy.

Key entities

  • Enlivex Ltd.

    Reports positive 12-month Phase I/IIa Allocetra results in moderate to severe knee osteoarthritis and provides Phase IIb topline timing.

  • Allocetra

    Investigational cell-based therapy for knee osteoarthritis, administered as three injections in a single treatment cycle.

  • ACR Convergence 2026

    Conference where the 12-month findings will be presented on November 8 in Orlando.

Related articles

$ENLVMedAI 8/10

Enlivex's Allocetra Secures FDA RMAT Designation For Knee Osteoarthritis Treatment

Enlivex Ltd. (ENLV) said the FDA granted RMAT designation to its Allocetra therapy for age-related symptomatic knee osteoarthritis in older adults. The RMAT decision cites results from its completed Phase I/IIa trial showing statistically significant improvements in pain and function vs placebo, durable to six months. Enlivex is starting a Phase IIb trial enrolling 182 patients and plans an FDA Type B meeting.